Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $32.8 million.

  • Altimmune's Total Liabilities rose 12672.74% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 12672.74%. This contributed to the annual value of $15.8 million for FY2024, which is 449.19% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Total Liabilities is $32.8 million, which was up 12672.74% from $29.0 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Total Liabilities ranged from a high of $32.8 million in Q3 2025 and a low of $14.5 million during Q3 2024
  • Its 5-year average for Total Liabilities is $19.5 million, with a median of $17.8 million in 2021.
  • Its Total Liabilities has fluctuated over the past 5 years, first tumbled by 3057.56% in 2021, then surged by 12672.74% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Total Liabilities stood at $19.7 million in 2021, then grew by 9.66% to $21.6 million in 2022, then fell by 23.55% to $16.5 million in 2023, then dropped by 4.49% to $15.8 million in 2024, then soared by 107.91% to $32.8 million in 2025.
  • Its Total Liabilities stands at $32.8 million for Q3 2025, versus $29.0 million for Q2 2025 and $15.1 million for Q1 2025.